Increase of the Ki67 Proliferation Index over Time in Patients with Neuroendocrine Neoplasms Abstract #1830

Introduction: Whether the Ki67 index increases over time in relation to progression is scarcely studied.
Aim(s): We investigated if Ki67 increased in patients with confirmed progressive disease.
Materials and methods: Thirty-five patients (21 men) with a median (range) age of 60 (39-76) years and a Ki67 < 20% at diagnosis and an increase of ≥8% at progression were included. The Ki67 was determined in hot spot areas either in surgical specimens or core biopsies from primary tumor or metastases at diagnosis and at progression evaluated by CT or SRI.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Pernille Holmager

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1892 Feasibility and Implication of Routine NGS Analysis in Neuroendocrine Carcinomas
Introduction: Neuroendocrine carcinomas (NECs) may arise from any organ system, exhibit various degree of differentiation and have Ki67 indices ranging from 21-100%. After first-line platin based chemotherapy, no standard treatment exists.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr. Ulrich Knigge
#2140 Neuroendocrine Neoplasms of the Appendix: Characterization of 251 Patients Referred to the Copenhagen NET Centre of Excellence
Introduction: Neuroendocrine neoplasms (NEN) of the appendix occur with an incidence of 0.15–0.6/100,000/year
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD, PhD Pernille Holmager
#1604 Resection of Liver Metastases in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinomas: A Nordic Multicenter Study
Introduction: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are generally characterized by synchronous metastases, high aggressiveness and a dismal prognosis. Currently, resection of liver metastases in patients with metastatic GEP-NEC is not recommended. However, the existing data are scarce.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: MD Renate Berget Galleberg
#1370 68Ga-DOTATOC PET and Gene Expression Profile in Patients with Neuroendocrine Carcinomas
Introduction: Somatostatin receptor expression on both protein and gene expression levels were compared with in vivo 68Ga-DOTATOC PET/CT in patients with neuroendocrine carcinomas (NEC).
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Ingrid Marie Holst Olsen
#1455 Expression of Mutated p53 Protein in Gastroenteropancreatic Neuroendocrine Carcinoma (WHO G3)
Introduction: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) are aggressive, highly proliferating tumors. Therapeutic response to current chemotherapy regimens is usually short-lasting.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: PhD student Abeir Ali
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.